Radiopharmaceuticals operate by combining radionuclides with carriers.The radiation energy emitted by radionuclides is utilized to selectively irradiate diseased tissues while minimizing damage to healthy tissues.In c...Radiopharmaceuticals operate by combining radionuclides with carriers.The radiation energy emitted by radionuclides is utilized to selectively irradiate diseased tissues while minimizing damage to healthy tissues.In comparison to external beam radiation therapy,radionuclide drugs demonstrate research potential due to their biological targeting capabilities and reduced normal tissue toxicity.This article reviews the applications and research progress of radiopharmaceuticals in cancer treatment.Several key radionuclides are examined,including^(223)Ra,^(90)Y,Lutetium-177(^(177)Lu),212 Pb,and Actinium-225(^(225)Ac).It also explores the current development trends of radiopharmaceuticals,encompassing the introduction of novel radionuclides,advancements in imaging technologies,integrated diagnosis and treatment approaches,and equipment-medication combinations.We review the progress in the development of new treatments,such as neutron capture therapy,proton therapy,and heavy ion therapy.Furthermore,we examine the challenges and breakthroughs associated with the clinical translation of radiopharmaceuticals and provide recommendations for the research and development of novel radionuclide drugs.展开更多
基金the National Key R&D Program of China(No.2023YFE0197700)the Fundamental Research Funds for the Central Universities(No.2632023TD04).
文摘Radiopharmaceuticals operate by combining radionuclides with carriers.The radiation energy emitted by radionuclides is utilized to selectively irradiate diseased tissues while minimizing damage to healthy tissues.In comparison to external beam radiation therapy,radionuclide drugs demonstrate research potential due to their biological targeting capabilities and reduced normal tissue toxicity.This article reviews the applications and research progress of radiopharmaceuticals in cancer treatment.Several key radionuclides are examined,including^(223)Ra,^(90)Y,Lutetium-177(^(177)Lu),212 Pb,and Actinium-225(^(225)Ac).It also explores the current development trends of radiopharmaceuticals,encompassing the introduction of novel radionuclides,advancements in imaging technologies,integrated diagnosis and treatment approaches,and equipment-medication combinations.We review the progress in the development of new treatments,such as neutron capture therapy,proton therapy,and heavy ion therapy.Furthermore,we examine the challenges and breakthroughs associated with the clinical translation of radiopharmaceuticals and provide recommendations for the research and development of novel radionuclide drugs.
